{"id":744966,"date":"2014-06-09T06:30:00","date_gmt":"2014-06-09T06:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-idenix\/"},"modified":"2023-03-22T00:04:54","modified_gmt":"2023-03-22T04:04:54","slug":"merck-to-acquire-idenix","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-idenix\/","title":{"rendered":"Merck to Acquire Idenix"},"content":{"rendered":"<p class=\"bwalignc\">       Acquisition Expands Portfolio of Promising Investigational Therapies        for Hepatitis C     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), today announced that the<br \/>\n      companies have entered into a definitive agreement under which Merck<br \/>\n      will acquire Idenix for $24.50 per share in cash. The transaction, which<br \/>\n      values the purchase of Idenix at approximately $3.85 billion, has been<br \/>\n      approved by the boards of directors of both companies.\n    <\/p>\n<p>\n      \u201cIdenix has established a promising portfolio of hepatitis C candidates<br \/>\n      based on its expertise in nucleoside\/nucleotide chemistry and prodrug<br \/>\n      technologies,\u201d said Dr. Roger Perlmutter, president, Merck Research<br \/>\n      Laboratories. \u201cIdenix\u2019s investigational hepatitis C candidates<br \/>\n      complement our promising therapies in development and will help advance<br \/>\n      our work to develop a highly effective, once-daily, all oral,<br \/>\n      ribavirin-free, pan-genotypic regimen that has a duration of treatment<br \/>\n      as short as possible for millions of patients in need around the world.\u201d\n    <\/p>\n<p>\n      Idenix is a biopharmaceutical company engaged in the discovery and<br \/>\n      development of medicines for the treatment of human viral diseases,<br \/>\n      whose primary focus is on the development of next-generation oral<br \/>\n      antiviral therapeutics to treat hepatitis C virus (HCV) infection. The<br \/>\n      company currently has three HCV drug candidates in clinical development:<br \/>\n      two nucleotide prodrugs (IDX21437 and IDX21459) and a NS5A inhibitor<br \/>\n      (samatasvir). These novel candidates are being evaluated for their<br \/>\n      potential inclusion in the development of all oral, pan-genotypic<br \/>\n      fixed-dose combination regimens.\n    <\/p>\n<p>\n      \u201cMerck has established a strong legacy of leadership and innovation in<br \/>\n      treating hepatitis C,\u201d said Ron Renaud, Idenix\u2019s President and Chief<br \/>\n      Executive Officer. \u201cThis agreement creates shareholder value by<br \/>\n      positioning Idenix\u2019s strong portfolio of candidates for future success<br \/>\n      with a leading healthcare company with the experience and commitment to<br \/>\n      develop fixed-dosed combinations with the potential to impact the global<br \/>\n      burden of hepatitis C.\u201d\n    <\/p>\n<p>\n      Merck\u2019s research and development portfolio includes several HCV<br \/>\n      medicines in development, the leading of which is a combination of<br \/>\n      MK-5172, an investigational HCV NS3\/4A protease inhibitor and MK-8742,<br \/>\n      an investigational HCV NS5A replication complex inhibitor. The<br \/>\n      combination of these two investigational candidates has received<br \/>\n      Breakthrough Therapy designation from the U.S. Food and Drug<br \/>\n      Administration for the treatment of HCV. In April 2014, Merck announced<br \/>\n      initiation of Phase 3 clinical trials for MK-5172\/MK-8742 to evaluate<br \/>\n      the combination with and without ribavirin in various genotypes and<br \/>\n      across a broad range of patient populations with chronic HCV. Study<br \/>\n      information can be found at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=50882303&amp;newsitemid=20140609005610&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=1&amp;md5=9404ae34376f6a9097b77fd090948b3f\" rel=\"nofollow\">www.clinicaltrials.gov<\/a>.\n    <\/p>\n<p>\n      Under the terms of the agreement, Merck, through a subsidiary, will<br \/>\n      initiate a tender offer to acquire all outstanding shares of Idenix<br \/>\n      Pharmaceuticals, Inc. The closing of the tender offer will be subject to<br \/>\n      certain conditions, including the tender of shares representing at least<br \/>\n      a majority of the total number of Idenix\u2019s outstanding shares (assuming<br \/>\n      the exercise of all options), the expiration of the waiting period under<br \/>\n      the Hart-Scott-Rodino Antitrust Improvements Act and other customary<br \/>\n      conditions. Upon the completion of the tender offer, Merck will acquire<br \/>\n      all remaining shares through a second-step merger. The companies expect<br \/>\n      the transaction to close in the third quarter of 2014.\n    <\/p>\n<p>\n      Credit Suisse acted as financial advisor to Merck in this transaction<br \/>\n      and Hughes Hubbard &amp; Reed LLP as its legal advisor. Centerview Partners<br \/>\n      acted as financial advisor to Idenix and Sullivan &amp; Cromwell as its<br \/>\n      legal advisor.\n    <\/p>\n<p>\n      <b>Important Information about the Tender Offer<\/b>\n    <\/p>\n<p>\n      The tender offer for the outstanding shares of Idenix has not yet<br \/>\n      commenced. This press release is for informational purposes only and is<br \/>\n      neither an offer to purchase nor a solicitation of an offer to sell<br \/>\n      shares, nor is it a substitute for the tender offer materials that Merck<br \/>\n      and its subsidiary will file with the Securities and Exchange Commission<br \/>\n      (SEC). At the time the planned tender offer is commenced, a tender offer<br \/>\n      statement on Schedule TO will be filed by Merck with the SEC and Idenix<br \/>\n      will file a solicitation\/recommendation statement on Schedule 14D-9,<br \/>\n      with respect to the tender offer. The tender offer materials (including<br \/>\n      an offer to purchase, a related letter of transmittal and other tender<br \/>\n      offer documents) and the solicitation\/recommendation statement will<br \/>\n      contain important information that holders of Idenix common stock shares<br \/>\n      are urged to read carefully when they become available, as each may be<br \/>\n      amended or supplemented from time to time, and because they will contain<br \/>\n      important information that holders of shares of Idenix common stock<br \/>\n      should consider before making any decision regarding tendering their<br \/>\n      shares. The tender offer materials will be made available to Idenix\u2019s<br \/>\n      stockholders at no expense to them. In addition, all of those materials<br \/>\n      (and other tender offer documents filed with the SEC) will be made<br \/>\n      available at no charge on the SEC\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50882303&amp;newsitemid=20140609005610&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=2893d711aa3a78aa3ef99baf8f8cc87d\" rel=\"nofollow\">www.sec.gov<\/a>.<br \/>\n      Additional copies of the tender offer materials may be obtained at no<br \/>\n      charge by contacting Merck at One Merck Drive, Whitehouse Station, NJ,<br \/>\n      08889 or by phoning (908) 423-1000. In addition, Merck and Idenix file<br \/>\n      annual, quarterly and current reports and other information with the<br \/>\n      SEC. You many read and copy any reports or other information filed by<br \/>\n      Merck or Idenix at the SEC public reference room at 100 F Street, N.E.,<br \/>\n      Washington, D.C., 20549. For further information on the SEC public<br \/>\n      reference room, please call 1-800-SEC-0330. Merck\u2019s and Idenix\u2019s filings<br \/>\n      with the SEC are also available to the public from commercial<br \/>\n      document-retrieval services and at the SEC\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50882303&amp;newsitemid=20140609005610&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=22f9170641641fe703529b7010c23aee\" rel=\"nofollow\">www.sec.gov<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50882303&amp;newsitemid=20140609005610&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=f96beab085373f86d7b9bdff8312ff5b\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=50882303&amp;newsitemid=20140609005610&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=8d5ff0d632741c63a63ab731376a6fd3\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=50882303&amp;newsitemid=20140609005610&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=97e5167ded6442e395c4678b45f838f0\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=50882303&amp;newsitemid=20140609005610&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=b3903b0d1f91312089874b836f50a353\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>About Idenix<\/b>\n    <\/p>\n<p>\n      Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in<br \/>\n      the discovery and development of drugs for the treatment of human viral<br \/>\n      diseases. Idenix is headquartered in Cambridge, Massachusetts (USA). Its<br \/>\n      clinical development operations and drug discovery operations are<br \/>\n      conducted in Cambridge and in the Company&#8217;s European laboratories in<br \/>\n      Montpellier, France. Idenix&#8217;s current focus is on the treatment of<br \/>\n      patients with hepatitis C infection.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Forward looking statements<br \/>\n      include statements regarding the timing and closing of the tender offer<br \/>\n      and the merger transactions, the ability of Merck to complete the<br \/>\n      transactions considering the various closing conditions, and any<br \/>\n      assumptions underlying any of the foregoing. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; the exposure to litigation, including patent<br \/>\n      litigation, and\/or regulatory actions; timing of the tender offer and<br \/>\n      merger; uncertainties as to how many Idenix stockholders will tender<br \/>\n      shares in the tender offer; the possibility that competing offer may be<br \/>\n      made; the possibility that various closing conditions to transactions<br \/>\n      may not be satisfied or waived, including that a governmental entity may<br \/>\n      prohibit, delay or refuse to grant approval for the consummation of the<br \/>\n      transactions; or that a material adverse effect occurs with respect to<br \/>\n      Idenix.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the SEC available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50882303&amp;newsitemid=20140609005610&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=11170a8ba78b783217ed2480db04bad4\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Idenix Forward Looking Statement<\/b>\n    <\/p>\n<p>\n      This press release contains &#8220;forward-looking statements&#8221; for purposes of<br \/>\n      the safe harbor provisions of The Private Securities Litigation Reform<br \/>\n      Act of 1995, including but not limited to the statements regarding the<br \/>\n      Company&#8217;s future business and financial performance. For this purpose,<br \/>\n      any statements contained herein that are not statements of historical<br \/>\n      fact may be deemed forward-looking statements. Without limiting the<br \/>\n      foregoing, the words &#8220;expect,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221;<br \/>\n      &#8220;will,&#8221; and similar expressions are also intended to identify<br \/>\n      forward-looking statements, as are expressed or implied statements with<br \/>\n      respect to the Company&#8217;s potential pipeline candidates, including any<br \/>\n      expressed or implied statements regarding the efficacy and safety of<br \/>\n      samatasvir, IDX21437 or IDX21459 or any other drug candidate; the<br \/>\n      successful development of novel combinations of direct-acting antivirals<br \/>\n      for the treatment of HCV; the likelihood and success of any future<br \/>\n      clinical trials involving samatasvir, IDX21437 or IDX21459 or any other<br \/>\n      drug candidates; and expectations with respect to funding of operations<br \/>\n      and future cash balances. Actual results may differ materially from<br \/>\n      those indicated by such forward-looking statements as a result of risks<br \/>\n      and uncertainties, including but not limited to the following: there can<br \/>\n      be no guarantees that the Company will advance any clinical product<br \/>\n      candidate or other component of its potential pipeline to the clinic, to<br \/>\n      the regulatory process or to commercialization; management&#8217;s<br \/>\n      expectations could be affected by unexpected regulatory actions or<br \/>\n      delays; uncertainties relating to, or unsuccessful results of, clinical<br \/>\n      trials, including additional data relating to the ongoing clinical<br \/>\n      trials evaluating its product candidates; the Company&#8217;s ability to<br \/>\n      obtain additional funding required to conduct its research, development<br \/>\n      and commercialization activities; changes in the Company&#8217;s business plan<br \/>\n      or objectives; the ability of the Company to attract and retain<br \/>\n      qualified personnel; competition in general; and the Company&#8217;s ability<br \/>\n      to obtain, maintain and enforce patent and other intellectual property<br \/>\n      protection for its product candidates and its discoveries. Such<br \/>\n      forward-looking statements involve known and unknown risks,<br \/>\n      uncertainties and other factors that may cause actual results to be<br \/>\n      materially different from any future results, performance or<br \/>\n      achievements expressed or implied by such statements. These and other<br \/>\n      risks which may impact management&#8217;s expectations are described in<br \/>\n      greater detail under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s annual<br \/>\n      report on Form 10-K for the year ended December 31, 2013 as filed with<br \/>\n      the SEC and in any subsequent periodic or current report that the<br \/>\n      Company files with the SEC.\n    <\/p>\n<p>\n      All forward-looking statements reflect the Company&#8217;s estimates only as<br \/>\n      of the date of this release (unless another date is indicated) and<br \/>\n      should not be relied upon as reflecting the Company&#8217;s views,<br \/>\n      expectations or beliefs at any date subsequent to the date of this<br \/>\n      release. While Idenix may elect to update these forward-looking<br \/>\n      statements at some point in the future, it specifically disclaims any<br \/>\n      obligation to do so, even if the Company&#8217;s estimates change.\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140609005610r2&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">Photos\/Multimedia Gallery Available: <\/span><span id=\"mmgallerylink-link\"><a href=\"http:\/\/www.businesswire.com\/multimedia\/home\/20140609005610\/en\/\" rel=\"nofollow\">http:\/\/www.businesswire.com\/multimedia\/home\/20140609005610\/en\/<\/a><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Steve        Cragle, 908-423-3461<br \/>or<br \/>Investors:<br \/>Joe Romanelli,        908-423-5185<br \/>Justin Holko, 908-423-5088<br \/>or<br \/>Idenix<br \/>Media\/Investors:<br \/>Teri        Dahlman, 617-995-9807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Acquisition Expands Portfolio of Promising Investigational Therapies for Hepatitis C Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), today announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash. The transaction, which values the purchase of Idenix at approximately $3.85 billion, has been approved by the boards of directors of both companies. \u201cIdenix has established a promising portfolio of hepatitis C candidates based on its expertise in nucleoside\/nucleotide chemistry and prodrug technologies,\u201d said Dr. Roger Perlmutter, president, Merck Research Laboratories. \u201cIdenix\u2019s investigational hepatitis C candidates complement our promising therapies in development and will help advance our work to develop a highly effective, once-daily, all oral, ribavirin-free, pan-genotypic regimen that has a duration of treatment as short as possible for<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-744966","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Acquire Idenix - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-idenix\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Acquire Idenix - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Acquisition Expands Portfolio of Promising Investigational Therapies for Hepatitis C Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), today announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash. The transaction, which values the purchase of Idenix at approximately $3.85 billion, has been approved by the boards of directors of both companies. \u201cIdenix has established a promising portfolio of hepatitis C candidates based on its expertise in nucleoside\/nucleotide chemistry and prodrug technologies,\u201d said Dr. Roger Perlmutter, president, Merck Research Laboratories. \u201cIdenix\u2019s investigational hepatitis C candidates complement our promising therapies in development and will help advance our work to develop a highly effective, once-daily, all oral, ribavirin-free, pan-genotypic regimen that has a duration of treatment as short as possible for\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-idenix\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:54+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140609005610r2&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-idenix\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-idenix\\\/\",\"name\":\"Merck to Acquire Idenix - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-idenix\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-idenix\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140609005610r2&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2014-06-09T06:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-idenix\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-idenix\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-idenix\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140609005610r2&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140609005610r2&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-idenix\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Acquire Idenix\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Acquire Idenix - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-idenix\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Acquire Idenix - Merck.com","og_description":"Acquisition Expands Portfolio of Promising Investigational Therapies for Hepatitis C Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), today announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash. The transaction, which values the purchase of Idenix at approximately $3.85 billion, has been approved by the boards of directors of both companies. \u201cIdenix has established a promising portfolio of hepatitis C candidates based on its expertise in nucleoside\/nucleotide chemistry and prodrug technologies,\u201d said Dr. Roger Perlmutter, president, Merck Research Laboratories. \u201cIdenix\u2019s investigational hepatitis C candidates complement our promising therapies in development and will help advance our work to develop a highly effective, once-daily, all oral, ribavirin-free, pan-genotypic regimen that has a duration of treatment as short as possible for","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-idenix\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:54+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140609005610r2&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-idenix\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-idenix\/","name":"Merck to Acquire Idenix - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-idenix\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-idenix\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140609005610r2&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en","datePublished":"2014-06-09T06:30:00+00:00","dateModified":"2023-03-22T04:04:54+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-idenix\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-idenix\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-idenix\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140609005610r2&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140609005610r2&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-idenix\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Acquire Idenix"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"f439b9be-f8c8-432d-bcc7-e454d5bb73e3","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2014\/06\/1\/logo_merck-logo.jpg","size":"13027","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2014\/06\/1\/idenix-5B1-5D.jpg","size":"8613","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-to-Acquire-Idenix-2014.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744966\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744966"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}